BFM
VRTX icon

Boothbay Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Boothbay Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,600
Closed -$14.2M – 1937
2024
Q3 		$14.2M Buy
+30,600
New +$14.7M 0.32% 38
2016
Q3 		– Sell
-3,800
Closed -$327K – 811
2016
Q2 		$327K Buy
+3,800
New +$328K 0.13% 225

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boothbay Fund Management's VRTX Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 1,320 shares worth $589K. The stake represents 0.01% of the portfolio and ranks #1255 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in VRTX as recently as Q3 2025.

Boothbay Fund Management first reported a position in VRTX in Q1 2017 and has held it in 16 quarters since. The position peaked at $2.95M in Q4 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Boothbay Fund Management held 1,320 shares of Vertex Pharmaceuticals worth $589K as of Q1 2026.
  • Vertex Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
  • Vertex Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1255 holding.
  • Boothbay Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 16 quarters since.
  • Boothbay Fund Management's Vertex Pharmaceuticals position peaked at $2.95M in Q4 2021.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.